BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 10,000 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $15.67, for a total value of $156,700.00. Following the completion of the sale, the chief marketing officer now directly owns 129,644 shares in the company, valued at approximately $2,031,521.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Todd Berard also recently made the following trade(s):

• On Wednesday, March 27th, Todd Berard sold 515 shares of BioLife Solutions stock. The stock was sold at an average price of $17.99, for a total value of $9,264.85.
• On Monday, March 11th, Todd Berard sold 401 shares of BioLife Solutions stock. The stock was sold at an average price of $17.42, for a total value of $6,985.42.
• On Wednesday, February 21st, Todd Berard sold 111 shares of BioLife Solutions stock. The stock was sold at an average price of $17.35, for a total value of $1,925.85.
• On Friday, January 19th, Todd Berard sold 1,232 shares of BioLife Solutions stock. The stock was sold at an average price of $16.76, for a total value of $20,648.32.

BioLife Solutions Trading Up 4.8 %

Shares of NASDAQ:BLFS opened at $15.86 on Friday. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $24.50. The stock has a market cap of $718.46 million, a PE ratio of -10.43 and a beta of 1.67. The business has a 50 day moving average of $17.50 and a 200-day moving average of $15.32. The company has a quick ratio of 1.83, a current ratio of 2.86 and a debt-to-equity ratio of 0.06.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. The business had revenue of $32.73 million during the quarter, compared to analysts’ expectations of $32.70 million. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. As a group, equities research analysts forecast that BioLife Solutions, Inc. will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently made changes to their positions in BLFS. HighTower Advisors LLC boosted its stake in shares of BioLife Solutions by 144.0% in the first quarter. HighTower Advisors LLC now owns 13,313 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 7,856 shares during the period. Citigroup Inc. boosted its stake in shares of BioLife Solutions by 38.6% in the first quarter. Citigroup Inc. now owns 24,924 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 6,937 shares during the period. MetLife Investment Management LLC boosted its stake in shares of BioLife Solutions by 55.4% in the first quarter. MetLife Investment Management LLC now owns 6,195 shares of the medical equipment provider’s stock valued at $141,000 after buying an additional 2,209 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of BioLife Solutions by 16.7% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,851 shares of the medical equipment provider’s stock valued at $588,000 after buying an additional 3,703 shares during the period. Finally, BlackRock Inc. lifted its stake in BioLife Solutions by 1.6% during the first quarter. BlackRock Inc. now owns 3,712,680 shares of the medical equipment provider’s stock worth $84,390,000 after purchasing an additional 57,623 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group began coverage on BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.40.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.